JNJ
J&J is still getting mileage out of ICOTYDE
Johnson & Johnson says new Phase 3 data from its ICONIC-LEAD study show ICOTYDE (icotrokinra) kept delivering at the 2-year mark in adults and adolescents with moderate-to-severe plaque psoriasis. The company says nearly three-quarters of patients achieved clear or almost clear skin after two years, which is the kind of sentence pharma companies love to say out loud because it sounds very investor-friendly.
Why the Street cares
This is not a flashy one-day pop headline. It’s more of a “the drug still has legs” update, and that can matter a lot in biotech-land. Durable efficacy plus a favorable safety profile is the combo meal investors want, especially in psoriasis where long-term treatment retention can make or break commercial potential.
The bigger J&J angle
For J&J, every solid readout helps reinforce the company’s broader pharma growth story. ICOTYDE is the first and only targeted oral peptide the company says precisely blocks the IL-23 receptor, which gives it a neat little differentiation pitch if future commercialization goes well.
Big picture
The market usually rewards drugs that don’t fizzle after the honeymoon phase. Two-year durability suggests ICOTYDE may be more than a one-hit clinical wonder — and that’s exactly the sort of thing investors like to see before the sales engine even starts warming up.